Drug intelligence / Profile preview

naphazoline hydrochloride

Development stage
Unknown
Lead developer
Novartis
Modality
Small Molecules
Administration
Intranasal, Ophthalmic
01

Overview

Naphazoline hydrochloride is a synthetic, direct-acting sympathomimetic amine and imidazole derivative that functions as a potent vasoconstrictor and decongestant. Originally patented in 1934 and introduced into medical use in 1942 by Ciba, the drug acts as an agonist on both alpha-1 and alpha-2 adrenergic receptors. Upon topical administration to the nasal mucosa or conjunctiva, naphazoline stimulates these receptors on vascular smooth muscle, causing rapid constriction of dilated arterioles. This localized vasoconstriction reduces blood flow, edema, and swelling, thereby providing temporary relief from nasal congestion associated with the common cold, sinusitis, and allergic rhinitis, as well as ocular redness and irritation caused by allergic conjunctivitis. It is widely available in over-the-counter (OTC) nasal sprays, nasal drops, and ophthalmic solutions.

Brand names
AlbalonClear EyesGotinalNafazolNaphconNeosoroPrivineVasocon
Other names
cloridrato de nafazolinanaphazolinenaphazoline hclnaphazoline hydrochloridenaphazoline hydrocloride
02

Targets

ADRA1A (α1A)ADRA1B (α1B)ADRA2A (α2A)ADRA2B (α2B)ADRA2C (α2C)ADRB1 (β1)DRD2 (Dopamine D2 Receptor)I1R (Nischarin)ADRA1D (α1D)

Beyond the preview

Go deeper on naphazoline hydrochloride.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on naphazoline hydrochloride.

Gosset Free

Get started with Gosset.

Enter your corporate email.

Work email preferred.

Book a call